Leuprolide - redOrbit

News - Leuprolide

New Data on Long-Term Use of FIRMAGONÂ® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology

2011-09-01 10:44:00

PARSIPPANY, N.J., Sept.

Abbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PEDÂ® (leuprolide acetate for depot suspension) for the Treatment of Central Precocious Puberty (CPP)

2011-08-16 14:19:00

ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S.

Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron DepotÂ® (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer

2011-06-20 08:00:00

ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S.

Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGONÂ® or Crossed Over to FIRMAGON From Leuprolide

2011-05-16 10:02:00

WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E.

Parenteral Depots Offer $8 Billion of Reformulation Opportunities and a Strong Competitive Edge in Crowded Pharmaceutical Space

2011-02-14 08:57:00

FALLS CHURCH, Va., Feb.

More News (103 articles) »

News - Leuprolide

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health